Association of low body temperature and poor outcomes in patients admitted with worsening heart failure

A substudy of the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trial

Saeed Payvar, John A. Spertus, Alan B. Miller, S. Ward Casscells, Peter Pang, Faiez Zannad, Karl Swedberg, Aldo P. Maggioni, Kimberly J. Reid, Mihai Gheorghiade

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims Risk stratification in patients admitted with worsening heart failure (HF) is essential for tailoring therapy and counselling. Risk models are available but rarely used, in part because many require laboratory and imaging results that are not routinely available. Body temperature is associated with prognosis in other illnesses, andwe hypothesized that low body temperature would be associated with worse outcomes in patients admitted with worsening HF. Methods and results The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial was an eventdriven, randomized, double-blind, placebo-controlled study of tolvaptan in 4133 patients hospitalized for worsening HF with an EF36.5°C) using Coxregression models. The composite ofCVdeath or HF rehospitalization occurred in 1544 patients within 1 year. For every 1°C decrease in body temperature, the risk of adverse outcomes increased by16%[hazard raio (HR) 1.16,95%confidence interval (CI) 1.04-1.28], after adjustment for age, gender, race, systolic blood pressure, EF, blood urea nitrogen, and serum sodium. In fully adjusted analysis, the risk of adverse outcomes in the lowest body temperature group (36.5°C) (HR 1.35, 95% CI 1.15-1.58). Conclusions Low body temperature is an independent marker of poor cardiovascular outcomes in patients admitted with worsening HF and reduced EF.

Original languageEnglish (US)
Pages (from-to)1382-1389
Number of pages8
JournalEuropean Journal of Heart Failure
Volume15
Issue number12
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Body Temperature
Vasopressins
Heart Failure
Outcome Assessment (Health Care)
Confidence Intervals
Blood Pressure
Blood Urea Nitrogen
tolvaptan
Counseling
Sodium
Placebos
Serum

Keywords

  • Body temperature
  • Heart Failure
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Association of low body temperature and poor outcomes in patients admitted with worsening heart failure : A substudy of the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trial. / Payvar, Saeed; Spertus, John A.; Miller, Alan B.; Ward Casscells, S.; Pang, Peter; Zannad, Faiez; Swedberg, Karl; Maggioni, Aldo P.; Reid, Kimberly J.; Gheorghiade, Mihai.

In: European Journal of Heart Failure, Vol. 15, No. 12, 2013, p. 1382-1389.

Research output: Contribution to journalArticle

Payvar, Saeed ; Spertus, John A. ; Miller, Alan B. ; Ward Casscells, S. ; Pang, Peter ; Zannad, Faiez ; Swedberg, Karl ; Maggioni, Aldo P. ; Reid, Kimberly J. ; Gheorghiade, Mihai. / Association of low body temperature and poor outcomes in patients admitted with worsening heart failure : A substudy of the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trial. In: European Journal of Heart Failure. 2013 ; Vol. 15, No. 12. pp. 1382-1389.
@article{c20b477dc67b44ef82b9b2df93f4eac1,
title = "Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: A substudy of the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trial",
abstract = "Aims Risk stratification in patients admitted with worsening heart failure (HF) is essential for tailoring therapy and counselling. Risk models are available but rarely used, in part because many require laboratory and imaging results that are not routinely available. Body temperature is associated with prognosis in other illnesses, andwe hypothesized that low body temperature would be associated with worse outcomes in patients admitted with worsening HF. Methods and results The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial was an eventdriven, randomized, double-blind, placebo-controlled study of tolvaptan in 4133 patients hospitalized for worsening HF with an EF36.5°C) using Coxregression models. The composite ofCVdeath or HF rehospitalization occurred in 1544 patients within 1 year. For every 1°C decrease in body temperature, the risk of adverse outcomes increased by16{\%}[hazard raio (HR) 1.16,95{\%}confidence interval (CI) 1.04-1.28], after adjustment for age, gender, race, systolic blood pressure, EF, blood urea nitrogen, and serum sodium. In fully adjusted analysis, the risk of adverse outcomes in the lowest body temperature group (36.5°C) (HR 1.35, 95{\%} CI 1.15-1.58). Conclusions Low body temperature is an independent marker of poor cardiovascular outcomes in patients admitted with worsening HF and reduced EF.",
keywords = "Body temperature, Heart Failure, Prognosis",
author = "Saeed Payvar and Spertus, {John A.} and Miller, {Alan B.} and {Ward Casscells}, S. and Peter Pang and Faiez Zannad and Karl Swedberg and Maggioni, {Aldo P.} and Reid, {Kimberly J.} and Mihai Gheorghiade",
year = "2013",
doi = "10.1093/eurjhf/hft113",
language = "English (US)",
volume = "15",
pages = "1382--1389",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Association of low body temperature and poor outcomes in patients admitted with worsening heart failure

T2 - A substudy of the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trial

AU - Payvar, Saeed

AU - Spertus, John A.

AU - Miller, Alan B.

AU - Ward Casscells, S.

AU - Pang, Peter

AU - Zannad, Faiez

AU - Swedberg, Karl

AU - Maggioni, Aldo P.

AU - Reid, Kimberly J.

AU - Gheorghiade, Mihai

PY - 2013

Y1 - 2013

N2 - Aims Risk stratification in patients admitted with worsening heart failure (HF) is essential for tailoring therapy and counselling. Risk models are available but rarely used, in part because many require laboratory and imaging results that are not routinely available. Body temperature is associated with prognosis in other illnesses, andwe hypothesized that low body temperature would be associated with worse outcomes in patients admitted with worsening HF. Methods and results The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial was an eventdriven, randomized, double-blind, placebo-controlled study of tolvaptan in 4133 patients hospitalized for worsening HF with an EF36.5°C) using Coxregression models. The composite ofCVdeath or HF rehospitalization occurred in 1544 patients within 1 year. For every 1°C decrease in body temperature, the risk of adverse outcomes increased by16%[hazard raio (HR) 1.16,95%confidence interval (CI) 1.04-1.28], after adjustment for age, gender, race, systolic blood pressure, EF, blood urea nitrogen, and serum sodium. In fully adjusted analysis, the risk of adverse outcomes in the lowest body temperature group (36.5°C) (HR 1.35, 95% CI 1.15-1.58). Conclusions Low body temperature is an independent marker of poor cardiovascular outcomes in patients admitted with worsening HF and reduced EF.

AB - Aims Risk stratification in patients admitted with worsening heart failure (HF) is essential for tailoring therapy and counselling. Risk models are available but rarely used, in part because many require laboratory and imaging results that are not routinely available. Body temperature is associated with prognosis in other illnesses, andwe hypothesized that low body temperature would be associated with worse outcomes in patients admitted with worsening HF. Methods and results The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial was an eventdriven, randomized, double-blind, placebo-controlled study of tolvaptan in 4133 patients hospitalized for worsening HF with an EF36.5°C) using Coxregression models. The composite ofCVdeath or HF rehospitalization occurred in 1544 patients within 1 year. For every 1°C decrease in body temperature, the risk of adverse outcomes increased by16%[hazard raio (HR) 1.16,95%confidence interval (CI) 1.04-1.28], after adjustment for age, gender, race, systolic blood pressure, EF, blood urea nitrogen, and serum sodium. In fully adjusted analysis, the risk of adverse outcomes in the lowest body temperature group (36.5°C) (HR 1.35, 95% CI 1.15-1.58). Conclusions Low body temperature is an independent marker of poor cardiovascular outcomes in patients admitted with worsening HF and reduced EF.

KW - Body temperature

KW - Heart Failure

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84890017041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890017041&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hft113

DO - 10.1093/eurjhf/hft113

M3 - Article

VL - 15

SP - 1382

EP - 1389

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 12

ER -